Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Kelly, Aaron S ^a   Bergenstal, Richard M ^b   Gonzalez Campoy, J M ^c   Katz, Harold ^d   Bank, Alan J ^e  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b INTERNATIONAL DIABETES CENTER   (United States)

^c Minnesota Center for Obesity Metabolism and Endocrinology   (United States)

^d Allina Hospitals & Clinics   (United States)

^e United Heart and Vascular Clinic   (United States)

Author keywords

Endothelial function; Exenatide; Metformin; Obesity; Pre diabetes

Indexed keywords

C REACTIVE PROTEIN; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ABDOMINAL OBESITY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPEREMIA; IMPAIRED GLUCOSE TOLERANCE; MALE; MICROVASCULAR ENDOTHELIAL CELL; ORAL GLUCOSE TOLERANCE TEST;

AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; ENDOTHELIUM, VASCULAR; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPEREMIA; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; LIPOPROTEINS, LDL; MALE; METFORMIN; MICROCIRCULATION; MIDDLE AGED; OBESITY, ABDOMINAL; PEPTIDES; PREDIABETIC STATE; TIME FACTORS; TREATMENT OUTCOME; UPPER EXTREMITY; VASCULAR CELL ADHESION MOLECULE-1; VENOMS;

EID: 84861944029     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-64     Document Type: Article

References (34)

1. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294. 2628695, 19017771.
2. Barr EL, Zimmet PZ, Welborn TA, Jolley D, Magliano DJ, Dunstan DW, Cameron AJ, Dwyer T, Taylor HR, Tonkin AM, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007, 116:151-157. 10.1161/CIRCULATIONAHA.106.685628, 17576864.
3. Meigs JB, Nathan DM, D'Agostino RB, Wilson PW. Fasting and postchallenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 2002, 25:1845-1850. 10.2337/diacare.25.10.1845, 12351489.
4. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006, 368:1096-1105.
5. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403. 1370926, 11832527.
6. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Hodis HN, Kitabchi AE, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 2011, 364:1104-1115. 10.1056/NEJMoa1010949, 21428766.
7. Giugliano D, Marfella R, Coppola L, Verrazzo G, Acampora R, Giunta R, Nappo F, Lucarelli C, D'Onofrio F. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997, 95:1783-1790.
8. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H. Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34:146-154. 10.1016/S0735-1097(99)00168-0, 10400004.
9. Koska J, Schwartz EA, Mullin MP, Schwenke DC, Reaven PD. Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. Diabetes Care 2010, 33:1028-1030. 10.2337/dc09-1961, 2858168, 20200309.
10. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000, 23:1830-1834. 10.2337/diacare.23.12.1830, 11128361.
11. Title LM, Cummings PM, Giddens K, Nassar BA. Oral glucose loading acutely attenuates endothelium-dependent vasodilation in healthy adults without diabetes: an effect prevented by vitamins C and E. J Am Coll Cardiol 2000, 36:2185-2191. 10.1016/S0735-1097(00)00980-3, 11127459.
12. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, Creager MA. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998, 97:1695-1701. 10.1161/01.CIR.97.17.1695, 9591763.
13. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, Goke B. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
14. Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis. Diabetes Obes Metab 2012, In Press.
15. Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract 2012, 18:227-237. 10.4158/EP11306.OR, 22446132.
16. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R, Watada H. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010, 59:1030-1037. 10.2337/db09-1694, 2844811, 20068138.
17. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350. 10.1161/CIRCULATIONAHA.107.739938, 18427132.
18. Erdogdu O, Nathanson D, Sjoholm A, Nystrom T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010, 325:26-35. 10.1016/j.mce.2010.04.022, 20452396.
19. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, Sjoholm A. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215. 10.1152/ajpendo.00237.2004, 15353407.
20. Oeseburg H, de Boer RA, Buikema H, van der HP, van Gilst WH, Sillje HH. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 2010, 30:1407-1414. 10.1161/ATVBAHA.110.206425, 20448207.
21. Ha SJ, Kim W, Woo JS, Kim JB, Kim SJ, Kim WS, Kim MK, Cheng XW, Kim KS. Preventive Effects of Exenatide on Endothelial Dysfunction Induced by Ischemia-Reperfusion Injury via KATP Channels. Arterioscler Thromb Vasc Biol 2012, 32:474-480. 10.1161/ATVBAHA.110.222653, 22155457.
22. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011, 10:22. 10.1186/1475-2840-10-22, 3070629, 21410975.
23. Xiao YF, Nikolskaya A, Jaye DA, Sigg DC. Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 2011, 10:6. 10.1186/1475-2840-10-6, 3037307, 21251280.
24. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
25. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. J Appl Physiol 2006, 101:545-548. 10.1152/japplphysiol.01285.2005, 16614356.
26. Bonetti PO, Pumper GM, Higano ST, Holmes DR, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004, 44:2137-2141. 10.1016/j.jacc.2004.08.062, 15582310.
27. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, Mitchell GF, Sheffy J, Vita JA, Benjamin EJ. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008, 117:2467-2474. 10.1161/CIRCULATIONAHA.107.748574, 2734141, 18458169.
28. Rubinshtein R, Kuvin JT, Soffler M, Lennon RJ, Lavi S, Nelson RE, Pumper GM, Lerman LO, Lerman A. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J 2010, 31:1142-1148. 10.1093/eurheartj/ehq010, 20181680.
29. Kelly AS, Metzig AM, Rudser KD, Fitch AK, Fox CK, Nathan BM, Deering M, Schwartz BL, Abuzzahab MJ, Gandrud LM, et al. Exenatide as a weight-loss therapy in extreme pediatric obesity: a randomized, controlled pilot study. Obesity (Silver Spring) 2012, 20:364-370.
30. Chaudhuri A, Ghanim H, Vora M, Sia CL, Korzeniewski K, Dhindsa S, Makdissi A, Dandona P. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrinol Metab 2012, 97:198-207. 10.1210/jc.2011-1508, 22013105.
31. Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439. 10.1016/S0140-6736(10)60590-9, 20580422.
32. Bunck MC, Diamant M, Eliasson B, Corner A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Jarvinen H, Smith U. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010, 33:1734-1737. 10.2337/dc09-2361, 2909051, 20424219.
33. Rosenstock J, Klaff LJ, Schwartz S, Northrup J, Holcombe JH, Wilhelm K, Trautmann M. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010, 33:1173-1175. 10.2337/dc09-1203, 2875418, 20332357.
34. Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010, 212:217-222. 10.1016/j.atherosclerosis.2010.05.028, 20557887.